{"id":17569,"date":"2026-02-18T17:48:33","date_gmt":"2026-02-18T17:48:33","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/17569\/"},"modified":"2026-02-18T17:48:33","modified_gmt":"2026-02-18T17:48:33","slug":"i-think-theyre-making-a-turn-here","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/17569\/","title":{"rendered":"\u201cI Think They\u2019re Making a Turn Here\u201d"},"content":{"rendered":"\n

Novo Nordisk A\/S (NYSE:NVO<\/a>) is one of the stocks Jim Cramer talked about, along with market froth<\/a>. During the episode, a caller asked if the stock is a buy, hold, or sell, and Cramer replied:<\/p>\n

No, I would hold it. I met with the CEO last week. I kind of, I liked him a lot. Now, I met with Dave Ricks from Lilly, and you know, he\u2019s my favorite, but I\u2019m not going to go against owning some Novo. I think they\u2019re making a turn here. I think that head start they have in the pill is very good.<\/p>\n

\"\" <\/p>\n

Photo by Adam Nowakowski<\/a> on Unsplash<\/a><\/p>\n

Novo Nordisk A\/S (NYSE:NVO) manufactures pharmaceuticals for chronic conditions, including diabetes, obesity, and rare blood or endocrine disorders. The company also produces some medical devices. Fundsmith<\/a> stated the following regarding Novo Nordisk A\/S (NYSE:NVO) in its fourth quarter 2025 investor letter<\/a>:<\/p>\n

Novo Nordisk A\/S (NYSE:NVO) managed to reaffirm my belief that you should never say \u2018Things can\u2019t get any worse\u2019. The company has parlayed a market leading position in what is probably the most exciting drug development for about three decades into a secondary position and has failed to prevent illegal generic competition in its core US market.<\/p>\n

While we acknowledge the potential of NVO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock<\/a>.<\/p>\n

READ NEXT: 30 Stocks That Should Double in 3 Years<\/a> and

Insider Monkey<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"Novo Nordisk A\/S (NYSE:NVO) is one of the stocks Jim Cramer talked about, along with market froth. During…\n","protected":false},"author":2,"featured_media":17570,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[271],"tags":[12581,2961,272],"class_list":{"0":"post-17569","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novo-nordisk","8":"tag-adam-nowakowski","9":"tag-jim-cramer","10":"tag-novo-nordisk"},"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/17569","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=17569"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/17569\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/17570"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=17569"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=17569"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=17569"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}